CN101052618A - 用作治疗阿尔茨海默氏病的β－分泌酶抑制剂的2－氨基吡啶化合物 - Google Patents

用作治疗阿尔茨海默氏病的β－分泌酶抑制剂的2－氨基吡啶化合物 Download PDF

Info

Publication number
CN101052618A
CN101052618A CNA2005800376837A CN200580037683A CN101052618A CN 101052618 A CN101052618 A CN 101052618A CN A2005800376837 A CNA2005800376837 A CN A2005800376837A CN 200580037683 A CN200580037683 A CN 200580037683A CN 101052618 A CN101052618 A CN 101052618A
Authority
CN
China
Prior art keywords
alkyl
compound
halogen
aryl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800376837A
Other languages
English (en)
Chinese (zh)
Inventor
C·A·科伯恩
M·K·霍洛维
S·J·施塔赫尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of CN101052618A publication Critical patent/CN101052618A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
CNA2005800376837A 2004-10-29 2005-10-25 用作治疗阿尔茨海默氏病的β－分泌酶抑制剂的2－氨基吡啶化合物 Pending CN101052618A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62344104P 2004-10-29 2004-10-29
US60/623,441 2004-10-29

Publications (1)

Publication Number Publication Date
CN101052618A true CN101052618A (zh) 2007-10-10

Family

ID=36565355

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800376837A Pending CN101052618A (zh) 2004-10-29 2005-10-25 用作治疗阿尔茨海默氏病的β－分泌酶抑制剂的2－氨基吡啶化合物

Country Status (7)

Country Link
US (1) US7932275B2 (https=)
EP (1) EP1807396B1 (https=)
JP (1) JP2008518969A (https=)
CN (1) CN101052618A (https=)
AU (1) AU2005310239A1 (https=)
CA (1) CA2585279A1 (https=)
WO (1) WO2006060109A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111533684A (zh) * 2020-05-29 2020-08-14 四川大学 一种吡啶化合物烯基化的方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) * 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
AU2006306542B2 (en) * 2005-10-21 2012-04-19 Merck Sharp & Dohme Corp. Potassium channel inhibitors
EP2402320A1 (en) 2006-03-31 2012-01-04 Novartis AG Anorectic agents
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
AU2009217518A1 (en) 2008-02-28 2009-09-03 Merck Sharp & Dohme Corp. 2-aminoimidazole beta-secretase inhibitors for the treatment of Alzheimer's disease
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
RU2014111055A (ru) 2011-08-22 2015-09-27 Мерк Шарп И Доум Корп. 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
JP6903825B2 (ja) * 2017-12-19 2021-07-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング γ−セクレターゼのモジュレーターとしてのトリアゾロピリジン

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
JP4251868B2 (ja) * 2000-08-11 2009-04-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 ２−アミノピリジン化合物および医薬用途
US6951946B2 (en) * 2002-03-19 2005-10-04 Lexicon Pharmaceuticals, Inc. Large scale synthesis of 1,2,4- and 1,3,4-oxadiazole carboxylates
US7132568B2 (en) 2002-06-17 2006-11-07 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
GB0305918D0 (en) * 2003-03-14 2003-04-23 Glaxo Group Ltd Novel compounds
WO2005005374A1 (en) 2003-06-16 2005-01-20 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
EP1831170A4 (en) 2004-12-14 2009-10-14 Astrazeneca Ab SUBSTITUTED AMINOPYRIDINES AND THEIR USE

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111533684A (zh) * 2020-05-29 2020-08-14 四川大学 一种吡啶化合物烯基化的方法

Also Published As

Publication number Publication date
US7932275B2 (en) 2011-04-26
WO2006060109B1 (en) 2006-08-10
EP1807396B1 (en) 2013-06-26
AU2005310239A1 (en) 2006-06-08
EP1807396A1 (en) 2007-07-18
CA2585279A1 (en) 2006-06-08
US20080161363A1 (en) 2008-07-03
WO2006060109A1 (en) 2006-06-08
JP2008518969A (ja) 2008-06-05
EP1807396A4 (en) 2009-09-09

Similar Documents

Publication Publication Date Title
CN101052618A (zh) 用作治疗阿尔茨海默氏病的β－分泌酶抑制剂的2－氨基吡啶化合物
CN1093130C (zh) 被取代的吡啶并6,6－二环衍生物
CN1191236C (zh) 取代的6,6－杂－双环衍生物
CN1859904A (zh) 用于治疗阿尔茨海默氏病的苄醚和苄氨基β－分泌酶抑制剂
CN1443165A (zh) 环戊二烯并吲哚、含有这类化合物的组合物及治疗方法
CN1835936A (zh) 用于治疗阿尔茨海默氏病的大环β－分泌酶抑制剂
CN1045580A (zh) 吡咯烷衍生物
CN1909897A (zh) 用于治疗阿尔茨海默病的苯基羧化物β－分泌酶抑制剂
CN1968924A (zh) 作为β－分泌酶抑制剂用于治疗阿尔茨海默氏病的吡咯烷－3－基化合物
CN1735597A (zh) 作为前列腺素激动剂的2－哌啶酮衍生物
CN1206407A (zh) 取代的乙烯基吡啶衍生物和含有它们的药物
CN101035760A (zh) 增强谷氨酸受体的化合物及其在药物中的应用
CN1768055A (zh) 作为代谢型谷氨酸受体－5调制剂的四环咪唑衍生物
CN1142827A (zh) Hiv蛋白酶抑制剂
CN1525972A (zh) 杂双环crf拮抗剂
CN1798744A (zh) 作为nmda/nr2b拮抗剂的3－氟－哌啶化合物
CN101061119A (zh) 治疗阿尔茨海默氏病的大环氨基吡啶β－分泌酶抑制剂
CN1256337C (zh) 抗抑郁的7,8－二氢－1,6,9－三氧杂－3－氮杂－环戊二烯并[a]萘的氮杂环基甲基衍生物
JP2020518555A (ja) 複素環ｐ２ｘ７アンタゴニスト
CN1267434C (zh) 抗抑郁的(SSSRI)7,8－二氢－3H－6,9－二氧杂－1,3－二氮杂环戊二烯并[a]萘的氮杂环基甲基衍生物
CN101035533A (zh) 抗精神分裂症的双重nk1/nk3拮抗剂
CN1017901B (zh) 抗精神病药稠环吡啶基哌嗪衍生物的制备方法
CN1960971A (zh) 取代的吡咯烷－2－酮
CN101068787A (zh) 8－苯基－5,6,7,8－氢喹啉速激肽受体拮抗剂
CN1377269A (zh) 玻璃体结合蛋白受体拮抗剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20071010

C20 Patent right or utility model deemed to be abandoned or is abandoned